Iohexol
- PDF / 169,217 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 67 Downloads / 155 Views
1 S
Fatal nephropathy: case report In a cross-sectional, prospective study involving 92 patients, who were followed up in the Trakya University, Turkey between August 2018 and September 2019, a patient [age and sex not stated] was described, who developed fatal nephropathy following administration of iohexol as a contract medium. The patient, who had cancer, received unspecified anti-vascular endothelial growth factor/receptor (anti-VEGF/R) therapy. Subsequently, the patient underwent thoracic CT and abdominal CT for evaluation chemotherapy response using IV iohexol 100mL (465 mOsmol/L) as a contract medium. Subsequently, the patient developed contrast-induced nephropathy [time to reaction onset not stated]. The patient also had chronic kidney damage and related complications. Eventually, the patient died due to nephropathy and kidney-related complications. Gokyer A, et al. Contrast nephropathy in cancer patients receiving anti-VEGF therapy: a prospective study. International Journal of Clinical Oncology 25: 1757-1762, No. 10, 803519525 Oct 2020. Available from: URL: http://doi.org/10.1007/s10147-020-01729-3
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
